全文获取类型
收费全文 | 191252篇 |
免费 | 18721篇 |
国内免费 | 8117篇 |
专业分类
耳鼻咽喉 | 2432篇 |
儿科学 | 4416篇 |
妇产科学 | 2072篇 |
基础医学 | 38202篇 |
口腔科学 | 5666篇 |
临床医学 | 14588篇 |
内科学 | 26850篇 |
皮肤病学 | 5057篇 |
神经病学 | 10252篇 |
特种医学 | 5888篇 |
外国民族医学 | 125篇 |
外科学 | 16203篇 |
综合类 | 28769篇 |
现状与发展 | 55篇 |
预防医学 | 5488篇 |
眼科学 | 3694篇 |
药学 | 14337篇 |
31篇 | |
中国医学 | 5897篇 |
肿瘤学 | 28068篇 |
出版年
2024年 | 128篇 |
2023年 | 2678篇 |
2022年 | 3402篇 |
2021年 | 6367篇 |
2020年 | 6246篇 |
2019年 | 6348篇 |
2018年 | 6577篇 |
2017年 | 6709篇 |
2016年 | 6960篇 |
2015年 | 7877篇 |
2014年 | 11516篇 |
2013年 | 12771篇 |
2012年 | 10950篇 |
2011年 | 12332篇 |
2010年 | 10154篇 |
2009年 | 9780篇 |
2008年 | 10201篇 |
2007年 | 10381篇 |
2006年 | 9389篇 |
2005年 | 8559篇 |
2004年 | 7636篇 |
2003年 | 6649篇 |
2002年 | 5451篇 |
2001年 | 4735篇 |
2000年 | 3907篇 |
1999年 | 3398篇 |
1998年 | 2854篇 |
1997年 | 2739篇 |
1996年 | 2312篇 |
1995年 | 2422篇 |
1994年 | 2196篇 |
1993年 | 1822篇 |
1992年 | 1401篇 |
1991年 | 1293篇 |
1990年 | 1045篇 |
1989年 | 969篇 |
1988年 | 888篇 |
1987年 | 702篇 |
1986年 | 666篇 |
1985年 | 969篇 |
1984年 | 933篇 |
1983年 | 647篇 |
1982年 | 695篇 |
1981年 | 555篇 |
1980年 | 472篇 |
1979年 | 390篇 |
1978年 | 277篇 |
1977年 | 214篇 |
1976年 | 201篇 |
1975年 | 101篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
利用生物信息学技术初步探索芫根调控肠道免疫功能的分子生物学机制。方法 选择雄性SPF级BALB/c小鼠18只,随机分为3组,每组6只。SC1组小鼠每只每次灌胃芫根提取液150 μL,SC2组小鼠每只每次灌胃绞碎芫根原浆悬液150 μL,NC组小鼠每只每次灌胃生理盐水150 μL,连续7 d每日灌胃一次。分别取每组小鼠小肠组织样品提取RNA,总RNA的质检合格后,进行转录组测序。按GO功能和KEGG信号通路对差异表达基因聚类分析揭示差异表达高度富集的免疫相关通路。从免疫角度分析芫根灌胃小鼠小肠组织的基因表达变化情况。结果 转录组测序共检测到27733条 mRNA的表达,SC1组与NC组比较,显著差异表达基因1635个,其中上调差异表达基因1236个,下调差异表达基因399个;SC2组与NC组比较,显著差异表达基因2872个,其中上调差异表达基因2233个,下调差异表达基因639个(P<0.05)。按GO功能和KEGG信号通路聚类分析显示差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路及维生素和脂肪消化吸收等途径的富集度在两个芫根组中均居于前20位(P<0.01),肠黏膜趋化因子CCL20和巨噬细胞极化标志物CD274等免疫蛋白编码基因差异表达显著且同属于上述多个免疫通路。结论 芫根灌胃小鼠小肠的差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路、营养物质消化吸收等途径高度富集,提示芫根对肠道免疫系统及肠黏膜功能的调节,其中CD274的表达上调和CCL20的表达下调提示诱导M1型巨噬细胞极化和T细胞活化可能是芫根调控免疫和维护肠道正常结构功能的重要途径。 相似文献
2.
3.
4.
5.
6.
《European journal of surgical oncology》2022,48(5):1062-1067
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease. 相似文献
7.
8.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
9.
《Transfusion and apheresis science》2022,61(2):103405
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare life-threatening complication of blood transfusion caused by donor T cells that escape rejection by the recipient immune system. These donor T cells drive recipient tissue damage in response to host antigens. On the other hand, GVHD occurring after allogeneic hematopoietic cell transplantation (HCT-GVHD) is also caused by donor T cells, but its pathophysiology is more complex and differs due to the effects of tissue damage caused by pre?HCT conditioning and profound immunosuppression. Both TA-GVHD and HCT-GVHD can be fatal; however, mortality is higher with TA-GVHD due to the paucity of treatment options. Here, we compare and summarize the presentation, diagnosis, pathophysiology, prevention, and treatment of TA-GVHD and HCT-GVHD. 相似文献
10.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献